Get the Stockscreener App
37.03
4.37%
-1.68
Crinetics Pharmaceuticals Inc stock is traded at $37.03, with a volume of 265.84K.
It is down -4.37% in the last 24 hours and down -25.09% over the past month.
Crinetics Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
See More
Previous Close:
$38.71
Open:
$38.58
24h Volume:
265.84K
Relative Volume:
0.33
Market Cap:
$3.59B
Revenue:
$4.72M
Net Income/Loss:
$-277.91M
P/E Ratio:
-9.9276
EPS:
-3.73
Net Cash Flow:
$-203.56M
1W Performance:
-8.14%
1M Performance:
-25.09%
6M Performance:
-23.35%
1Y Performance:
-2.01%
1-Day Range:
$37.00
$39.18
1-Week Range:
$37.04
$40.88
52-Week Range:
$35.51
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Name
Crinetics Pharmaceuticals Inc
Sector
Industry
Phone
858-450-6464
Address
10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO, CA
Compare CRNX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
37.03 | 3.59B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.04 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.08 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
652.89 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.69 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.71 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-04-25 | Initiated | Wolfe Research | Peer Perform |
| Jan-22-25 | Upgrade | Jefferies | Hold → Buy |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Jan-16-24 | Initiated | Morgan Stanley | Overweight |
| Dec-21-23 | Initiated | Jefferies | Hold |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Oct-24-23 | Resumed | Cantor Fitzgerald | Overweight |
| Aug-31-23 | Initiated | Oppenheimer | Outperform |
| Apr-24-23 | Initiated | Piper Sandler | Overweight |
| Mar-30-23 | Initiated | Robert W. Baird | Outperform |
| Nov-30-21 | Initiated | JMP Securities | Mkt Outperform |
| Nov-23-21 | Initiated | Evercore ISI | Outperform |
| Jun-18-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-23-19 | Initiated | ROTH Capital | Buy |
| Feb-14-19 | Initiated | H.C. Wainwright | Buy |
| Aug-13-18 | Initiated | JP Morgan | Neutral |
| Aug-13-18 | Initiated | Leerink Partners | Outperform |
| Aug-13-18 | Initiated | Piper Jaffray | Overweight |
View All
Crinetics Pharmaceuticals Inc Stock (CRNX) Latest News
Jennison Associates LLC Has $138.48 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $195,350.00 in Stock - MarketBeat
Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025 - The Manila Times
Crinetics Q4 Earnings Date Confirmed: Key Financial Updates Expected Feb 27 - StockTitan
Crinetics Pharmaceuticals Inc (CRNX)’s Market Momentum: Closing Strong at 39.30, Down -2.72 - The Dwinnex
An analyst sees good growth prospects for Crinetics Pharmaceuticals Inc (CRNX) - SETE News
Calamos Advisors LLC Reduces Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - MarketBeat
Wolfe Research Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX) - Defense World
Crinetics Pharmaceuticals exec sells shares worth $195,350 - MSN
Crinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest Losers - Insider Monkey
Keeping an Eye on Crinetics Pharmaceuticals Inc (CRNX) After Insider Trading Activity - Knox Daily
Wolfe Research Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Peer Perform Recommendation - MSN
KBC Group NV Grows Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) - Defense World
Wolfe starts Crinetics at Peer Perform, believes hedge funds turning bearish - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Wolfe Research - MarketBeat
Wolfe Research Initiates Coverage on Crinetics Pharmaceuticals With Peer Perform Rating - Marketscreener.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Vanguard Group Inc's Strategic Acquisition of Crinetics Pharmace - GuruFocus.com
What Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)? - MSN
(CRNX) On The My Stocks Page - Stock Traders Daily
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of “Buy” by Brokerages - Defense World
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by SG Americas Securities LLC - MarketBeat
Analysts Set Expectations for CRNX FY2025 Earnings - Defense World
Crinetics upgraded to buy by Jefferies, atumelnant potential cited - MSN
Jefferies turns bullish on Crinetics stock, citing overlooked CAH market potential - MSN
Jefferies Financial Group Upgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) to "Buy" - MarketBeat
Brokers Offer Predictions for CRNX FY2025 Earnings - MarketBeat
This Netflix Analyst Turns Bullish; Here Are Top 5 Upgrades For Wednesday - Benzinga
Is Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks? - Insider Monkey
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Increase in Short Interest - MarketBeat
Crinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2%Here's Why - MarketBeat
Crinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside Potential - Insider Monkey
12 Biotech Stocks with the Biggest Upside Potential - Insider Monkey
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Up 3.12%: This Is What Analysts Are Now Forecasting - Stocks Register
Crinetics falls after mid-stage trial data adrenal disorder therapy - MSN
Crinetics Pharmaceuticals (NASDAQ:CRNX) Receives “Buy” Rating from HC Wainwright - Defense World
Crinetics Pharmaceuticals' (CRNX) Buy Rating Reiterated at HC Wainwright - MarketBeat
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by JPMorgan Chase & Co. - Defense World
CRNXCrinetics Pharmaceuticals, Inc. Latest Stock News & Market Updates - StockTitan
Crinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Crinetics Pharmaceuticals Grants Stock Options to 17 New Employees in Key Expansion Move - StockTitan
Crinetics reports positive results in CAH treatment study By Investing.com - Investing.com Australia
Crinetics stock falls after CAH therapy data (CRNX:NASDAQ) - Seeking Alpha
Crinetics Pharmaceuticals (NASDAQ:CRNX) Sees Unusually-High Trading VolumeStill a Buy? - MarketBeat
Crinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2 - TipRanks
Crinetics reports positive results in CAH treatment study - Investing.com India
Crinetics Pharmaceuticals Inc Stock (CRNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Crinetics Pharmaceuticals Inc Stock (CRNX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Feb 03 '25 |
Sale |
39.07 |
5,000 |
195,350 |
31,748 |
0.61%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):